Mixed
Combining supervised exercise with GLP-1 receptor agonist (liraglutide) during weight loss maintenance significantly improves the sustainability of weight loss and body composition one year after treatment termination compared to using GLP-1 receptor agonist alone.
If you are using GLP-1 medications (like liraglutide or semaglutide) for weight loss, do not rely on the medication alone for long-term maintenance. The study shows that stopping the medication leads to significant weight regain. To prevent this, you must incorporate supervised exercise (specifically vigorous cycling and circuit training) during your treatment phase. This combination builds the behavioral and physiological resilience needed to maintain your weight loss even after you stop the medication.
One year after treatment termination, participants who had previously received combined supervised exercise and GLP-1 receptor agonist treatment had maintained weight loss and body-fat reduction, in contrast to weight regain for participants who had previously received GLP-1 receptor agonist alone.
Why this rating
Randomized, placebo-controlled trial with a rigorous post-treatment follow-up phase, though the post-treatment sample size was reduced due to attrition.
Source
Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial
Simon Birk Kjær Jensen et al. · EClinicalMedicine · 2024
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →